ERIBULIN* ANTIBODY-DRUG CONJUGATE (ADC) PAYLOAD
Eribulin-based ADCs have durable anti-tumor effects in PDX models
TRIPLE NEGATIVE BREAST CANCER
Triple-negative Breast Cancer
BYSTANDER EFFECTS OF ERIBULIN ADC PAYLOAD DEMONSTRATED IN PRECLINICAL MODELS**
ERIBULIN RELEASED VIA ENDOSOMAL PROCESSING OF THE ADC DISPLAYS SUBNANOMOLAR MITOTIC AND NON-MITOTIC EFFECTS ON BOTH THE TUMOR AND TUMOR MICROENVIRONMENT
- The mitotic effects eribulin exhibited as a payload not only include direct cytotoxic effects on receptor-positive cells bound by the ADC, but also on neighboring receptor-negative tumor cells.
- This bystander effect on neighboring receptor-negative tumor cells showed synergistic reduction in growth of heterogeneous patient-derived xenograft (PDX) tumors.
- Furthermore, released eribulin is highly cytotoxic to the stromal cancer-associated fibroblasts that are critical to supporting tumor growth in many cancers.
ERIBULIN ALSO HAS COMPLEX NON-MITOTIC EFFECTS ON THE TUMOR MICROENVIRONMENT
- Eribulin induces vascular remodeling and increases blood perfusion in tumors, thus making a greater percentage of the tumor susceptible and sensitive to subsequently administered therapies.
- Eribulin promotes a mesenchymal-to-epithelial transition (MET) phenotype in tumors, leading to reduced metasticity, reduced immunosuppression and increased drug sensitivity.
**These preclinical models do not imply clinical safety or efficacy.
*Any ADC employing eribulin as a payload is investigational and has not been approved by regulatory authorities. For more information on Halaven® (eribulin mesylate), please see www.halaven.com or contact Eisai’s Medical Information toll-free number: 1-888-274-2378.